| Literature DB >> 33767200 |
Jing Zou1, Xuping Xie1, Camila R Fontes-Garfias1, Kena A Swanson2, Isis Kanevsky2, Kristin Tompkins2, Mark Cutler2, David Cooper2, Philip R Dormitzer3, Pei-Yong Shi4,5,6,7.
Abstract
Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7-2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.Entities:
Year: 2021 PMID: 33767200 PMCID: PMC7994717 DOI: 10.1038/s41541-021-00313-8
Source DB: PubMed Journal: NPJ Vaccines ISSN: 2059-0105 Impact factor: 7.344